Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug

Carfilzomib is a last generation proteasome inhibitor (PI) with proven clinical efficacy in the treatment of relapsed/refractory multiple myeloma. This drug is considered to be extremely specific in inhibiting the chymotrypsin-like activity of the 20S proteasome, encoded by the β5 subunit, overcomin...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Grazia Raffaella Tundo, Diego Sbardella, Francesco Oddone, Giuseppe Grasso, Stefano Marini, Maria Grazia Atzori, Anna Maria Santoro, Danilo Milardi, Francesco Bellia, Gabriele Macari, Grazia Graziani, Fabio Polticelli, Paolo Cascio, Mariacristina Parravano, Massimo Coletta
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2022-02-01
coleção:	Biomolecules
Assuntos:	proteasome carfilzomib insulin-degrading enzyme cancer neurodegeneration
Acesso em linha:	https://www.mdpi.com/2218-273X/12/2/315
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!